Stanford sleep medicine professor Emmanuel Mignot won the 2023 Breakthrough Prize in Life Sciences in September for discovering the cause of narcolepsy, a chronic disorder that disrupts sleep-wake ...

For the estimated 200,000 Americans with narcolepsy, sleep is an unpredictable part of life. While the condition affects people differently, it can involve uneven slumber, sleep paralysis, and ...

A Craig Reynolds Professor of Sleep Medicine has been crowned the winner of a 2023 Breakthrough Prize in Life Science at Stanford University Medical School. Ian Mackey Unsplash A Craig Reynolds ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a person to ...

Narcolepsy causes uncontrollable "sleep attacks" during your daily activities, regardless of how much sleep you get. You may have hallucinations, and sleep paralysis can occur when you are falling ...

There are two forms of narcolepsy. In type 1, cataplexy is another symptom that involves sudden muscle weakness or paralysis. This symptom can occur suddenly and is usually when a person experiences ...

This informational guide, part of POPSUGAR's Condition Center, lays out the realities of this health concern: what it is, what it can look like, and strategies that medical experts say are proven to ...

The richest award in science is going to a Stanford sleep scientist and other top thinkers in their fields, named winners of the glitzy Breakthrough Prize on Thursday morning. Dr. Emmanuel Mignot of ...

Narcolepsy is a rare condition that will make someone fall asleep abruptly — even in the middle of the day during an activity. It's possible to treat narcolepsy and manage your symptoms with lifestyle ...

Hypersomnia and narcolepsy are both sleep disorders that cause excessive daytime sleepiness and other changes in natural sleep-wake cycles. "Hypersomnia" actually refers to several sleep conditions ...

FDA Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton as a Potential First-in-Class Therapy ...